Physician profile
Myron I Liebhaber
NPI 1346253390
$354,093.57
in general payments reported to CMS, 2019-2025
36 companies · $21K in 2025
The $21K reported for 2025 was more than what 92% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146K · 2020: $44K · 2021: $32K · 2022: $44K · 2023: $43K · 2024: $23K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $39K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Food and Beverage: $6,804 · Travel and Lodging: $6,462 · Honoraria: $4,500 · Education: $43.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $39,113.38 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,772.00 |
| Food and Beverage | $6,803.96 |
| Travel and Lodging | $6,462.48 |
| Honoraria | $4,500.00 |
| Education | $43.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $110,678.49 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67,346.59 | 2020-2025 | Cinryze, Takhzyro, Cuvitru |
| Pharming Healthcare, INC. | $57,481.51 | 2019-2025 | Ruconest |
| Phadia US INC. | $38,739.85 | 2019-2025 | Immunocap |
| Grifols USA, LLC | $21,786.71 | 2019-2024 | Xembify, Prolastin-C Liquid |
| Csl Behring | $18,232.98 | 2019-2025 | Andembry, Haegarda, Hizentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16,239.33 | 2019-2023 | Spiriva, Spiriva Respimat, Stiolto Respimat |
| Pfizer INC. | $6,763.32 | 2019-2024 | |
| Biocryst Pharmaceuticals, INC. | $4,934.91 | 2019-2020 | |
| Genentech USA, INC. | $2,077.78 | 2019-2024 | Xolair |
| Biocryst US Sales Co., LLC | $1,812.14 | 2021-2025 | Orladeyo |
| Blueprint Medicines Corporation | $1,805.00 | 2020-2024 | |
| Glaxosmithkline, LLC. | $1,619.82 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $861.54 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $858.01 | 2019-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $670.01 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $354.86 | 2019-2024 | |
| Optinose US, INC. | $316.17 | 2019-2024 | |
| Incyte Corporation | $244.02 | 2021-2025 | Opzelura |
| Alk-Abello, INC | $229.27 | 2019-2023 | Grastek, Odactra, Ragwitek |
| Amgen INC. | $222.47 | 2021-2025 | Tezspire, Actimmune |
| Ionis Pharmaceuticals, INC. | $100.57 | 2025 | Dawnzera |
| Teva Pharmaceuticals USA, INC. | $92.75 | 2019-2021 | |
| Sobi, INC | $92.27 | 2020 | |
| Octapharma USA, INC. | $89.37 | 2020-2023 | Cutaquig |
| Ars Pharmaceuticals Operations, INC. | $73.03 | 2025 | Neffy |
| Hikma Pharmaceuticals USA | $68.64 | 2023-2025 | Ryaltris |
| Greer Laboratories, INC. | $65.22 | 2024-2025 | Oralair, Palforzia |
| Kaleo, INC. | $41.95 | 2020-2021 | |
| Bio Products Laboratory USA, INC. | $36.85 | 2019-2020 | |
| Cycle Pharmaceuticals INC | $33.68 | 2025 | Sajazir |
| Organon LLC | $31.50 | 2025 | Nexplanon |
| Horizon Therapeutics Plc | $27.55 | 2020 | |
| Covis Pharma Gmbh | $25.54 | 2022 | |
| Aimmune Therapeutics, INC. | $20.51 | 2023 | |
| Merck Sharp & Dohme LLC | $19.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myron Liebhaber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.